United States-based AbbVie (NYSE: ABBV) has acquired Seattle-based Mavupharma, it was reported yesterday.
Mavupharma is a company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer. Its lead clinical candidate is MAVU-104, a first-in-class, orally active, small molecule inhibitor of ENPP1, an enzyme involved in the regulation of the STING pathway. Inhibiting ENPP1 activity with MAVU-104 allows for highly controlled enhancement of STING signalling in tumours without the need for injections.
Financial terms of the deal were not revealed.
Steve Davidsen, PhD, vice president of oncology discovery, AbbVie, said, 'AbbVie's vision in oncology is to advance breakthrough areas of science leading to a strong pipeline of innovative cancer therapies. Mavupharma's platform has the potential to further our immuno-oncology portfolio and assist in the development of transformative medicines for patients.'
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Flamingo Therapeutics names new director
Merck reports lung cancer trial failed to meet endpoints
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886
University of Saskatchewan Partners with SOPHiA GENETICS in landmark ovarian cancer trial